MHRA (UK)Original article
MHRA concludes review of Avacopan Vifor following reassessment of benefit-risk balance
RegulatoryAvacopan ViforNeutral
AI Analysis
Summary
The MHRA has concluded its review of Avacopan Vifor, a treatment for rare autoimmune diseases affecting small blood vessels, following a reassessment of the drug's benefit-risk balance. The article provides no details on the outcome of this review.
Outcome Details
MHRA concluded review following reassessment of benefit-risk balance
Importance:3/10
Sentiment:
0.00
MHRAregulatory reviewbenefit-risk assessmentrare diseaseautoimmune
Read the original article
Published by MHRA (UK) on September 1, 2026 9:25 AM